Functionally, HRP2lo MM cells are speculated to have higher H3K27me3 levels and are more sensitive to inhibitors targeting H3K27me3, such as the EZH2 inhibitor tazemetostat. The gene discussed is EZH2; the disease is Miyoshi myopathy.